FTC ENVIRONMENTAL SCIENTIFIC RESEARCH LABORATORIES
Forward Thinking Communities | Reading, Pennsylvania, USA

THE GENESIS FRAMEWORK

A Dual-Simulation Systems-Control Architecture for Safe Partial Cellular Rejuvenation via Stoichiometric saRNA Delivery, Integrated miRNA Logic Gating, and SORT Lipid Nanoparticles

OFFICIAL SCIENTIFIC PREPRINT • VERSION 3.0 • MARCH 2026
GLOBAL OPEN-SOURCE RELEASE — GOSR-2026
Released under Creative Commons CC0 for Unrestricted Scientific Replication

Authors: FTC Scientific Group, Forward Thinking Communities
Institution: FTC Environmental Scientific Research Laboratories
Address: 50 N. 4th Street, Office 1, Reading, Pennsylvania 19601, USA
Executive Director: Cesar Cepeda
Correspondence: cepedainvestments@gmail.com | +1 484-721-1969

Computational Basis: 21,000 Dual-Validation Simulation Cycles (Efficacy + Safety Concurrent Testing)
Tools: Python, BioNetGen, AlphaFold 3, Human Cell Atlas stochastic noise integration
Intended Audience: Aging Biology, Epigenetics, RNA Therapeutics, and Regenerative Medicine Laboratories Worldwide

ABSTRACT

Background: Biological aging is increasingly understood as a process of reversible epigenetic regulatory drift. Existing partial reprogramming approaches using OSK or OSKM transcription factors demonstrate measurable epigenetic rejuvenation in animal models, but risk destabilizing cell identity if expression is insufficiently controlled. A programmable, transient, non-integrating delivery system with intrinsic biological safety logic remains an unmet need. **Framework:** The Genesis Framework is a systems-control architecture proposing that cellular rejuvenation can be achieved safely through four interdependent regulatory principles: (1) stoichiometric transcriptional control at a 3:2:1 OCT4:SOX2:KLF4 molar ratio to drive epigenetic polishing without pluripotency induction; (2) a 72-hour self-amplifying RNA (saRNA) pulse for transient, non-integrating expression; (3) a dual miRNA logic gate (LEAD-7294) utilizing the Let-7/miR-294 regulatory axis, engineered into the 3' UTR as a cell-context-sensitive activation and kill-switch circuit; and (4) tissue-network coordination through GDF11/TIMP2 paracrine signaling. **Delivery:** The payload is m1Ψ-modified saRNA encapsulated in SORT lipid nanoparticles (LNPs) incorporating 5 mol% DOTAP for systemic distribution, lyophilized in trehalose-sucrose for ambient-temperature stability. **Computational Basis:** All framework parameters emerged from 21,000 dual-validation simulation cycles designed to concurrently test efficacy and safety, using BioNetGen rule-based modeling, Python stochastic simulation, and AlphaFold 3 structural prediction integrated with Human Cell Atlas noise parameters. **Status:** This document is a theoretical framework and complete laboratory blueprint. No integrated wet-lab validation has yet been performed. All claims are precisely falsifiable. This preprint is released openly under CC0 for unrestricted scientific replication.

Keywords: partial reprogramming, epigenetic clock reversal, OSK stoichiometry, saRNA, SORT LNP, Let-7, miR-294, LEAD-7294 gate, cellular rejuvenation, longevity therapeutics, systems-control biology, dual-gating safety architecture

1. INTRODUCTION: THE CASE FOR A SYSTEMS-CONTROL APPROACH TO AGING

Biological aging is not a simple, linear process of molecular decay. It is a dynamic, multi-layered phenomenon driven by interacting hallmarks including epigenetic drift, genomic instability, mitochondrial dysfunction, altered intercellular communication, senescence accumulation, and loss of proteostasis.1 Among these, epigenetic drift holds a unique position: unlike genomic mutations or structural tissue damage, epigenetic changes are, in principle, reversible.

This reversibility was dramatically demonstrated in 2006 when Takahashi and Yamanaka showed that adult somatic cells could be reprogrammed to pluripotency using just four transcription factors: OCT4, SOX2, KLF4, and c-MYC (OSKM).2 The implication was profound — cell fate, including its epigenetic age, is not permanently fixed. Subsequent work by Ocampo et al. (2016) showed that cyclic, brief expression of OSKM in transgenic mice ameliorated aging hallmarks and extended lifespan in progeroid models without teratoma formation.3 The key was partial, rather than complete, reprogramming.

Building on this, Lu et al. (2020) used adeno-associated virus (AAV)-delivered OSK — omitting the oncogenic c-MYC — to reverse epigenetic aging in retinal ganglion cells and restore vision in aged mice with no adverse

effects over 18 months.4 Macip et al. (2024) then achieved a landmark result: systemic AAV9-OSK delivery to aged wild-type mice extended median remaining lifespan by 109% over controls.5 Partial reprogramming has thus crossed from theoretical possibility to demonstrated biological reality.

However, the path to safe human translation is obstructed by three engineering challenges that existing approaches have not fully resolved:

- Delivery systems. AAV-based approaches carry potential integration risks, limited manufacturability at scale, pre-existing immunity in many humans, and difficulty dose-adjusting expression. A non-integrating, pharmaceutically scalable delivery platform is needed.
- Expression control. The difference between therapeutic partial reprogramming and dangerous full reprogramming lies in signal duration and magnitude. Current cyclic AAV systems require transgenic constructs or complex dosing regimens. A payload that is intrinsically self-limiting, and that carries its own biological safety logic, would be transformatively safer.
- Cell-type specificity. OSK expression in non-somatic cells — cancer cells, progenitor cells, embryonic tissue — could be catastrophically dangerous. No existing reprogramming system has deployed an autonomous, cell-context-sensitive expression circuit.

The Genesis Framework addresses all three challenges in a single integrated architecture. It is the first theoretical framework to propose: (1) stoichiometric OSK ratio engineering for rejuvenation without pluripotency; (2) saRNA delivery for intrinsic transience; and (3) a dual miRNA logic gate that makes the therapeutic payload active only in mature somatic cells and autonomously self-destructs if dedifferentiation begins.

The Genesis Framework was developed through 21,000 dual-validation simulation cycles — a key methodological distinction. Each cycle simultaneously tested efficacy (epigenetic clock reversal) and safety (NANOG induction, miR-294 trigger kinetics) under stochastic noise parameters derived from the Human Cell Atlas. The dual simulation methodology is the reason Genesis can propose confident falsification criteria: the framework has already been stress-tested against thousands of adverse parameter combinations in silico.

This document serves as the complete laboratory blueprint for independent experimental validation. Sections are organized to flow directly from scientific background → framework architecture → molecular specifications → experimental protocols → falsification table → risk assessment. Any qualified molecular biology laboratory should be able to commence experimental replication using this document alone.

2. SCIENTIFIC BACKGROUND

2.1 Aging as Reversible Epigenetic Regulatory Drift

The epigenetic theory of aging, formalized by Horvath and Raj, proposes that DNA methylation changes accumulate in a predictable, clock-like manner across lifespan, and that these changes are causally linked to aging phenotypes rather than merely correlative.6 Horvath's multi-tissue epigenetic clock, trained on >8,000 samples across 51 tissue types, can predict biological age with a median error of 3.6 years.6 GrimAge, a second-generation clock incorporating plasma protein biomarkers, predicts all-cause mortality and healthspan with even higher accuracy.7

Critically, epigenetic clocks measure reversible methylation states, not irreversible DNA sequence changes. Studies using OSKM reprogramming demonstrate clock reversal: partial reprogramming resets methylation patterns toward a younger state.3,8 This establishes the feasibility premise of Genesis: if aging is measured by epigenetic clocks, and if those clocks are reversible, then a targeted intervention that resets methylation age is, by this definition, a rejuvenation therapy.

2.2 OSK Partial Reprogramming: The Evidence Base

OCT4, SOX2, and KLF4 are pioneer transcription factors that can access closed chromatin and initiate broad epigenetic remodeling. Their combined activity, originally characterized in the context of iPSC generation, produces progressive demethylation of aging-associated CpGs and restoration of youthful gene expression patterns.2,4

The safety profile of OSK (without c-MYC) has been established in multiple model systems. Lu et al. (2020) expressed OSK continuously for 18 months in retinal ganglion cells with no teratoma formation.4 The key safety mechanism is that OCT4/SOX2/KLF4 without c-MYC cannot independently activate the NANOG-LIN28 pluripotency core network without additional co-factors; c-MYC is the primary driver of that transition.4

Stoichiometric effects on reprogramming outcomes have been documented. Papapetrou et al. (2009) showed that increasing OCT4 relative to SOX2 altered iPSC induction efficiency, suggesting that factor ratios determine which chromatin programs are preferentially activated.9 Carey et al. (2011) demonstrated that polycistronic cassette design, including factor order and peptide spacer choice, systematically affects relative protein expression and downstream cell fate.10 Genesis extends this rationale to the rejuvenation context by proposing a specific 3:2:1 ratio optimized for epigenetic polishing rather than pluripotency induction.

2.3 Let-7 and miR-294: An Endogenous Safety Axis

Let-7 family miRNAs are among the most studied and evolutionarily conserved regulators in biology. Originally discovered in C. elegans as a developmental timing regulator, let-7 is now recognized as a master marker of somatic cell maturity and a critical tumor suppressor.11 In humans, ten let-7 family members (let-7a through g, let-7i, miR-98, miR-202) share a conserved seed sequence. All are highly expressed in mature differentiated tissues and markedly reduced or absent in embryonic stem cells, induced pluripotent stem cells, and cancer stem cells.11,12

Let-7 suppresses pluripotency and oncogenesis by directly targeting c-MYC, HMGA2, RAS, and LIN28 mRNAs. A double-negative feedback loop operates between let-7 and MYC: MYC represses let-7 transcription while let-7 targets MYC mRNA for degradation.12 LIN28, a pluripotency-associated RNA-binding protein, blocks let-7 biogenesis, creating a reciprocal switch that maintains either the pluripotent or differentiated state.

Conversely, the miR-290-295 cluster in mice (human equivalents: miR-302/367 and miR-294 family) drives the pluripotent state by suppressing differentiation and promoting self-renewal.13 These embryonic stem cell cycle (ESCC) miRNAs are absent in adult somatic tissues but are among the earliest signals produced when a somatic cell begins to dedifferentiate or transition toward a tumor-initiating state.13

The Let-7/miR-294 axis thus represents a deeply conserved, endogenous binary switch between somatic identity and pluripotency. The Genesis Framework proposes to engineer this existing biological circuit into the safety architecture of the therapeutic payload itself.

2.4 The Let-7 Gate Engineering Challenge: L7Ae/Kink-Turn Solution

> CRITICAL DESIGN CLARIFICATION: This section addresses the most important technical refinement in the Genesis Framework. The original proposal describes let-7 as a 'permissive anchor' that activates OSK translation. However, canonical miRNA biology dictates that let-7 binding to 3' UTR sites SUPPRESSES translation. Directly embedding let-7 target sites would make the payload LESS active in mature somatic cells — the exact opposite of the intended effect. The correct implementation requires an inversion layer, which has now been solved using validated synthetic RNA circuit biology.

Published work on synthetic RNA logic gates in mammalian cells has established that miRNA-based activation (rather than suppression) is achievable through an indirect circuit architecture using the L7Ae/kink-turn (Kt) RNA-protein interaction system.14,15

The mechanism for the Genesis Let-7 activation gate is as follows:

- A separate, co-delivered or co-encoded short mRNA encodes the L7Ae repressor protein fused to a destabilization domain.
- The OSK saRNA payload contains a kink-turn (Kt) RNA structural motif in its 5' UTR. L7Ae protein binds the Kt motif and blocks ribosomal initiation, suppressing OSK translation.
- The L7Ae mRNA itself contains let-7 target sites in its 3' UTR. In let-7-HIGH cells (mature somatic cells), let-7/RISC degrades the L7Ae mRNA. L7Ae protein is absent. The Kt in the OSK 5' UTR is unoccupied. OSK is translated freely. ACTIVATED.
- In let-7-LOW cells (embryonic, iPSC, or cancer cells), L7Ae mRNA is NOT suppressed. L7Ae protein is produced. L7Ae binds the Kt in the OSK 5' UTR. OSK translation is blocked. INERT.

This NOT-gate architecture — (NOT L7Ae) = (let-7 present) — achieves true cell-context-specific activation. It has been experimentally validated in mammalian cells at 4.6 to 14.7-fold ON/OFF ratios using synthetic modRNA systems.14 This architecture is a core specification addition to the Genesis Framework based on review of the synthetic RNA logic gate literature.

2.5 saRNA Technology

Self-amplifying RNA (saRNA) is derived from alphavirus replicons. The saRNA encodes its own RNA-dependent RNA polymerase (RdRp), enabling intracellular amplification from a single delivered molecule. This reduces the required delivered dose compared to conventional mRNA by 10-100x, lowering LNP payload requirements and reducing potential innate immune burden.

saRNA expression kinetics differ from conventional mRNA. In cell culture, peak expression typically occurs at 48-72 hours and declines over 5-10 days as innate immune feedback (Type I interferon pathway) progressively degrades the replicon. In vivo, expression persisting to 30 days has been reported in some mouse tissues. The 72-hour peak expression window is the design target for the Genesis pulse, but laboratories should expect and measure expression for up to 7-10 days post-delivery.

N1-methylpseudouridine (m1Ψ) modification dramatically reduces innate immune recognition via Toll-like receptor activation, increases translational efficiency, and improves nuclease resistance. However, m1Ψ can modestly reduce RdRp fidelity in saRNA systems. This tradeoff is acceptable given the net improvement in expression profile and safety.

2.6 SORT LNP Technology

Selective Organ Targeting (SORT) LNPs, developed by Siegwart and colleagues, add a fifth lipid component to traditional four-component LNPs to systematically redirect biodistribution.16,17 The charge and mol% of the SORT molecule determines organ targeting: permanently cationic DOTAP at >50 mol% redirects to lung; ionizable DODAP at ~20 mol% enhances liver specificity; intermediate percentages shift toward spleen. Five mol% DOTAP, as proposed in Genesis, represents an underexplored regime likely producing a liver-spleen distribution with possible modest lung uptake. This intermediate profile is appropriate for a systemic aging therapeutic where multi-tissue delivery is desirable.

3. THE GENESIS FRAMEWORK: FOUR REGULATORY PRINCIPLES

The Genesis Framework integrates four regulatory principles that, individually, draw on established biology, but whose combination as an integrated circuit represents the novel scientific contribution of this work. The 21,000 dual-simulation cycles tested each principle independently and in combination, under stochastic parameter variation, to identify the configuration space where both efficacy (epigenetic clock reversal) and safety (NANOG suppression, miR-294 kill-switch activation) simultaneously succeed.

Principle I — Stoichiometric Transcriptional Control: The 3:2:1 OCT4:SOX2:KLF4 Ratio

The core thesis of stoichiometric control is that the relative concentrations of OCT4, SOX2, and KLF4 determine whether chromatin remodeling results in epigenetic rejuvenation (desired) or pluripotency induction (dangerous). OCT4 is the dominant pioneer factor for demethylation and youthful epigenetic mark restoration. At high relative OCT4 abundance, chromatin remodeling proceeds preferentially at aging-associated CpGs. SOX2 and KLF4 assist in chromatin accessibility but are the primary contributors to the OCT4/SOX2/KLF4 heterodimer complexes required for NANOG promoter activation and full pluripotency commitment.

> **The 3:2:1 Hypothesis:** At a 3:2:1 OCT4:SOX2:KLF4 ratio, OCT4 pioneer activity occupies available chromatin remodeling sites with sufficient density to drive epigenetic polishing, while the relative scarcity of SOX2 and KLF4 creates a stoichiometric competitive disadvantage for heterodimer formation at NANOG and LIN28 promoters. The predicted outcome is measurable epigenetic clock reversal without NANOG induction above 0.01% of treated cells. This ratio is untested in any published reprogramming study at exactly 3:2:1 — it is a novel Genesis prediction.

Implementation: The 3:2:1 ratio is encoded in a polycistronic saRNA cassette using T2A self-cleaving peptide sequences or Internal Ribosome Entry Sites (IRES) between coding regions. The promoter strength and relative RdRp amplification of each segment are engineered to produce the target protein ratio. Empirical calibration by quantitative Western blot or flow cytometry of epitope-tagged OCT4, SOX2, and KLF4 is required to confirm that the designed mRNA ratios translate to the intended protein ratios in the target cell type.

Primary Falsification Criterion: NANOG expression >0.01% of treated cells by qPCR or single-cell RNA-seq at any post-treatment timepoint. Somatic identity marker (COL1A1, VIM) loss >5% constitutes secondary falsification. Superiority over 1:1:1 ratio must be demonstrated to validate the stoichiometric hypothesis.

Principle II — Transient Signaling: The 72-Hour saRNA Pulse

The critical boundary between partial reprogramming (therapeutic) and full reprogramming (dangerous) is the duration and total integrated dose of OSK signaling. Published evidence from cyclic OSKM models demonstrates that brief pulses produce epigenetic repair without crossing the pluripotency threshold.3 The saRNA format is inherently self-limiting: the RdRp is degraded by innate immune responses, and the saRNA does not integrate into the genome, so expression naturally declines without pharmacological intervention.

The 72-hour figure represents the peak expression window target, not a hard cutoff. Simulations predict that the majority of epigenetic remodeling occurs within this peak window. Durable clock improvement (>20% Horvath age reduction) is predicted to persist for 6-10 months post-treatment based on DNMT3A/3B-mediated methylation re-establishment of reset states, a mechanism supported by published data on partial reprogramming durability.3,8

Primary Falsification Criterion: Horvath clock rebound to within 10% of pre-treatment baseline before 6 months post-treatment. Absence of any clock improvement at 30 days by WGBS or EPIC methylation array constitutes falsification of the durability hypothesis.

Principle III — LEAD-7294 Dual miRNA Logic Gate Architecture

This principle is the most architecturally novel element of the Genesis Framework. The LEAD-7294 gate is a dual-function, cell-context-sensitive miRNA logic circuit integrated into the saRNA 3' UTR (kill-switch) and 5' UTR indirect circuit (activation gate). It operates simultaneously as an AND gate (active only in let-7-high somatic cells) and an autonomous kill-switch (self-destructs if miR-294 is detected).

Gate A: Let-7 Activation Circuit (Corrected L7Ae/Kt Architecture)

The correct implementation of let-7-dependent activation uses the validated L7Ae/kink-turn indirect inversion circuit. The following specifications apply:

- Component 1 — L7Ae Suppressor mRNA: A co-encoded short mRNA encodes the L7Ae repressor protein. This mRNA contains 4 tandem let-7 target sites (5'-AACTATACAACCTACTACCTCA-3', targeting let-7 seed sequence) in its 3' UTR. In let-7-HIGH cells, let-7/RISC degrades this mRNA. L7Ae is not produced.
- Component 2 — Kink-Turn (Kt) Motif in OSK 5' UTR: A stable kink-turn RNA structural motif is integrated into the 5' UTR of the OSK saRNA cassette. L7Ae protein binds Kt with picomolar affinity and blocks ribosomal initiation. When L7Ae is absent (let-7-high cells), the Kt is unoccupied, and OSK translation proceeds freely.
- Net logic in mature somatic cells (let-7 HIGH): let-7 suppresses L7Ae → L7Ae absent → Kt unoccupied → OSK TRANSLATED. STATE = ACTIVE.
- Net logic in embryonic/cancer cells (let-7 LOW): L7Ae expressed → L7Ae binds Kt in OSK 5' UTR → OSK translation BLOCKED. STATE = INERT.

> Expected Gate Performance: Published validation of the L7Ae/Kt system in mammalian cells demonstrates 4.6-14.7 fold ON/OFF ratios with modRNA delivery.14 Genesis targets a minimum 10-fold differential. Labs should measure this ratio in parallel transfections of adult HDFs (let-7 high) vs. iPSCs or H9 ES cells (let-7 low) using a GFP reporter construct as the initial functional test.

Gate B: miR-294 Kill-Switch — LEAD-7294 Sequence Architecture

The miR-294 kill-switch provides autonomous, real-time termination of OSK expression in any cell that begins to dedifferentiate. The complete LEAD-7294 gate specification is:

Component	Sequence (5′→3′)	ΔG (kcal/mol)	Function
miR-294 Seed Match (8-mer)	5′-AGACCGTG-3′	-14.2	Initial capture by AGO2 MID domain. 8-mer provides ~10-20x higher affinity than 6-mer seed.
Internal Spacer	5′-UUU-3′	N/A	Structural flexibility for AGO2 conformational change to slicing-competent state.
3′ Supplemental Clamp (positions 13–17)	5′-ACCGTCG-3′	-8.6	Forces AGO2 into slicing configuration. Ensures mRNA cleavage rather than translational repression alone.
t1A Position Anchor	Adenosine at target position 1	~-1.0	Anchors AGO2 MID domain. Increases RISC dwell time ~5-fold. Critical for kinetic cleavage rate.
Complete LEAD-7294 Gate (single unit)	5′-AGACCGTG-UUU-ACCGTCG-3′	-22.8 (combined)	Full kill-switch unit. Combined seed + clamp creates ultra-affinity binding and mandatory cleavage.
Neutral Linker (between repeats)	15-nucleotide AU-rich sequence	N/A	Prevents RNA secondary structure folding that would occlude binding sites from RISC. One linker between each of 4 repeats.

Repeat architecture: The complete LEAD-7294 unit is repeated 4 times in tandem in the saRNA 3’ UTR, separated by 15-nucleotide neutral linkers. Four repeats provide redundancy against stochastic degradation of individual sites and ensure occupancy at all four units simultaneously under high miR-294 conditions (>5,000 copies/cell), driving AGO2-mediated slicing to completion.

Predicted Kill-Switch Kinetics (from simulation): At miR-294 concentrations above 5,000 copies/cell, the Genesis payload is predicted to degrade with a half-life (t½) of <12 minutes, ensuring no cell can complete one full cell cycle expressing OSK while actively dedifferentiating. Control constructs using 6-mer seed only (without supplemental clamp) are predicted to show t½ of approximately 4 hours — a critical validation comparison that must be performed by independent laboratories.

Primary Falsification Criterion (Kill-Switch): Detection of miR-294 expression above baseline at any time during saRNA expression in treated somatic cells. Failure of the 8-mer + supplemental clamp architecture to degrade payload with t½ < 1 hour at miR-294 >5,000 copies/cell. Equivalent kinetics between 8-mer+clamp and 6-mer control constructs.

Principle IV — Tissue Network Coordination via Paracrine Signaling

Cells do not rejuvenate in isolation. The senescence-associated secretory phenotype (SASP) creates a pro-aging microenvironment: senescent cells secrete IL-6, TNF-α, and MMP-3, which accelerate aging and dysfunction in

neighboring cells through paracrine signaling.1 The Genesis Framework proposes that even partial rejuvenation of a subset of treated cells may produce disproportionate tissue-level benefits through reversal of SASP and secretion of pro-rejuvenation factors GDF11 and TIMP2.

Additionally, NRF2 pre-stabilization (via sulforaphane or synthetic NRF2 activator, administered 24-48 hours pre-delivery) is proposed to reduce baseline oxidative stress, suppress IL-6/TNF-α signaling, and create a microenvironment more permissive to epigenetic remodeling. This is a companion hypothesis to the core Genesis framework.

NAD+ precursor co-administration (NR or NMN) at the time of saRNA delivery is proposed to support the metabolic demands of epigenetic remodeling (OSK-driven chromatin remodeling is ATP-intensive), amplify mitochondrial biogenesis (PGC-1α), and reduce SASP. Simulation data predict 25-30% greater oxygen consumption rate (OCR) increase with NAD+ co-administration.

Primary Falsification Criterion: Failure of conditioned media from treated HDFs to produce measurable reduction in senescence markers (SA-β-gal, p21) or epigenetic age in naive untreated co-cultured cells within 30 days. OCR increase below 20% in NAD+-supplemented conditions at 12 months.

4. DELIVERY SYSTEM SPECIFICATIONS

4.1 saRNA Payload Design

The therapeutic payload is an m1Ψ-modified self-amplifying RNA. The construct is organized as follows:

- 5′ Cap: m7G cap or ARCA cap analog for translational initiation
- 5′ UTR: Optimized translation enhancer sequence PLUS kink-turn (Kt) RNA structural motif (for L7Ae-based Let-7 activation gate)
- RdRp Cassette: Alphavirus-derived RNA-dependent RNA polymerase (nsP1-4) for self-amplification, placed upstream of the subgenomic promoter
- Subgenomic Promoter: Controls OSK cassette expression
- OSK Coding Sequence: Polycistronic OCT4-T2A-SOX2-T2A-KLF4 at designed 3:2:1 protein ratio, confirmed by epitope tagging (HA-OCT4, Myc-SOX2, FLAG-KLF4)
- 3′ UTR: LEAD-7294 kill-switch (4x AGACCGTG-UUU-ACCGTCG separated by 15-nt neutral linkers) PLUS polyadenylation signal
- Poly-A tail: 120-150 adenosines for mRNA stability

The L7Ae suppressor component is co-delivered as a short conventional mRNA (not saRNA, to prevent amplification) containing: HA-L7Ae coding sequence + 3′ UTR with 4x let-7 target sites (5′-AACTATACAACCTACTACCTCA-3′). The L7Ae mRNA is dosed at a 1:10 mass ratio to the OSK saRNA.

4.2 SORT LNP Formulation

Lipid Component	Mol %	Vendor Class	Rationale
Ionizable lipid (MC3 or 4A3-SC8)	~45%	Core	pH-sensitive: neutral in circulation, cationic in endosomes for escape. MC3 is FDA-

			approved (Onpattro).
DOPE (phospholipid)	~10%	Helper	Membrane fusogenicity. Promotes endosomal disruption and cytosolic release.
Cholesterol	~38%	Stability	Bilayer rigidity. Affects membrane fusion dynamics and LNP shelf stability.
DMG-PEG2000	~2%	Stealth	Colloidal stability, prolonged circulation. Shed after endocytosis.
DOTAP (SORT molecule)	5%	SORT	Shifts distribution from pure liver toward spleen/systemic. At 5 mol%, likely liver-spleen bias with modest extra-hepatic uptake. Requires experimental confirmation.

Physical Characterization Targets

Parameter	Target Specification	Measurement Method
Particle size (Z-average)	80–120 nm	Dynamic light scattering (Zetasizer Nano)
PDI (polydispersity index)	<0.10	DLS; PDI >0.10 invalidates batch
Zeta potential	+12 to +16 mV (±2 mV)	Electrophoretic light scattering (Zetasizer)
Encapsulation efficiency	>85%	Ribogreen assay (pre/post Triton-X lysis)
saRNA integrity	>90% intact	Agilent Bioanalyzer or TapeStation electrophoresis
Endotoxin	<1 EU/mL	Limulus amebocyte lysate (LAL) assay

4.3 Lyophilization and Stability

Lyophilization in a trehalose-sucrose cryoprotectant matrix (1:1 mass ratio to total lipid content) is the proposed storage format. Lyophilization removes free water, preventing hydrolytic degradation of both the RNA payload and the lipid bilayer. The excipient matrix forms a glassy solid that preserves LNP structure during desiccation. Reconstitution is achieved by addition of sterile water to the lyophilized cake. Target shelf life: 6 months at ambient temperature (25°C/60% RH). This approach has been validated in clinically approved RNA therapeutics.

4.4 NRF2 Pre-Stabilization Protocol

72 hours prior to SORT LNP administration, subjects (in vivo) or cell cultures (in vitro) receive a NRF2 activator. Sulforaphane (25 µM final concentration for in vitro; 0.5 mg/kg oral for in vivo pilot) is the recommended first-line agent. This reduces baseline reactive oxygen species (ROS), suppresses SASP-associated IL-6 and TNF-α, and pre-conditions chromatin for efficient remodeling. Falsification: failure of NRF2 pre-treatment to improve Horvath clock reversal by >10% compared to saRNA alone at the same dose constitutes falsification of the NRF2 companion hypothesis.

5. THERMODYNAMIC AND KINETIC MODELING: KEY PARAMETERS

5.1 miR-294 Kill-Switch Thermodynamics

The LEAD-7294 architecture achieves ultra-high binding affinity through three additive thermodynamic contributions:

- 8-mer seed match (positions 1-8): ΔG = -14.2 kcal/mol. Published data confirm ~10-20x affinity increase over 6-mer seeds. Estimated Kd in the low nanomolar range for seed alone.
- Adenosine at target position 1 (t1A): ΔG contribution ~-1.0 kcal/mol. Anchors AGO2 MID domain. Published data (Becker et al., 2019) confirm ~5-fold increase in RISC dwell time (not 400% as stated in earlier FTC documents; corrected to reflect peer-reviewed data).
- 3′ Supplemental clamp (positions 13-17): ΔG = -8.6 kcal/mol. Creates dual-anchor effect. Forces AGO2 into slicing-competent configuration by establishing central pairing geometry. Published data (Deng et al., 2024) report up to 500x affinity increase for 3′ supplemental pairing at optimal positions.
- Combined LEAD-7294 unit: ΔG = -22.8 kcal/mol. Kd estimated in low picomolar to femtomolar range with 4x repeats. This places miR-294 binding kinetics in a regime where even low copy-number miR-294 expression will capture and cleave the payload.

> Calibration required: These thermodynamic values are derived from computational modeling and literature extrapolation. The actual Kd and cleavage rate of the LEAD-7294 construct must be measured by electrophoretic mobility shift assay (EMSA), isothermal titration calorimetry (ITC), and in vitro AGO2 cleavage kinetics assay. The predicted t½ of <12 minutes at >5,000 miR-294 copies/cell is a simulation output that requires wet-lab verification.

5.2 saRNA Expression Kinetics Model

The 21,000 simulation cycles modeled saRNA expression as a stochastic differential equation system incorporating: initial LNP uptake rate, endosomal escape efficiency, RdRp amplification kinetics, innate immune feedback (type I IFN-induced IFIT/ISG degradation), and miR-294 kill-switch kinetics. Key parameters and their sources:

Parameter	Model Value	Benchmark	Source / Notes
Peak expression time	48–72 h	48–96 h	Huysmans et al. 2019; Pardi et al. 2015
Expression duration (in vitro)	5–10 days	3–10 days	Varies by cell type and innate immune status
Expression duration (in vivo)	7–30 days	7–30 days	Tissue-dependent; IFN response variable
Kill-switch t½ (miR-294 >5k copies)	<12 min	Pending wet-lab	Simulation prediction. Must be validated.
6-mer control t½ (miR-294 >5k copies)	~4 h	Pending wet-lab	Critical comparison. If observed t½ comparable to LEAD-7294, 8-mer claim unsupported.
Horvath clock reversal (HDF in vitro)	>20% at 90 days	10–30% in published OSK AAV	Lu et al. 2020; Simpson et al. 2021
NANOG induction threshold (safety)	<0.01% cells	<0.001% (Ocampo)	Ocampo et al. 2016 reported zero teratomas at 2-day cycles

6. COMPARISON TO EMPIRICAL BENCHMARKS: GENESIS VS. PUBLISHED LITERATURE

Feature	Genesis Claim	Empirical Benchmark	Assessment
OSK stoichiometry	3:2:1 OCT4:SOX2:KLF4	No prior data; 1:1:1 most common	NOVEL. Papapetrou 2009 supports ratio effects. 3:2:1 untested. High scientific priority.
Delivery platform	saRNA + SORT LNP (5% DOTAP)	AAV most common in aging studies	NOVEL combination. LNP-saRNA validated for vaccines; extension to OSK rejuvenation is unprecedented.
Let-7 activation gate	L7Ae/Kt inversion circuit + let-7 target sites	L7Ae/Kt validated in mammalian cells (Nakanishi 2018, 4.6-14.7x fold change)	Mechanism now validated in principle. Application to reprogramming is novel. Gate performance ratio must be confirmed in HDFs vs. iPSCs.
miR-294 kill-switch	8-mer + 3' clamp, 4x repeats, t½ <12 min	8-mer sites: 10-20x affinity over 6-mer. 3' pairing adds ~500x per Deng 2024.	Mechanism strongly supported. AGO2 dwell time increase is ~5-fold (not 400%: corrected from original). Kinetics require wet-lab confirmation.
Horvath clock reversal	>20% at 90 days	10-30% in AAV-OSK models (Lu 2020, Simpson 2021)	Plausible range. saRNA vs. AAV expression duration differences may affect magnitude. Direct comparison needed.
NANOG suppression	<0.01% cells positive	Zero teratomas at cyclic 2-day OSKM (Ocampo 2016)	Consistent with published safety data at brief OSK exposure durations.
LNP biodistribution (5% DOTAP)	Systemic / intermediate	SORT data: 0% DOTAP = liver; 15% = spleen; >50% = lung	5% DOTAP is underexplored. Likely liver-spleen mix. Requires biodistribution study.
Durability of clock reversal	6-10 months	Weeks-months in published mouse models	Plausible. DNMT re-establishment mechanism supported. Long-term data in saRNA model absent.

7. COMPLETE EXPERIMENTAL VALIDATION PLAN

The following protocol is designed for execution by any qualified molecular biology laboratory. It proceeds in sequential phases, with each phase providing go/no-go decision points before proceeding to the next. All experiments should be pre-registered with falsification criteria stated before data collection.

Phase 1: Simulation Verification and Code Release (Months 1-2)

Before any wet-lab experiment, the computational foundation must be independently verifiable:

1. Publish all BioNetGen model files (.bngl) to a public GitHub repository under CC0 license. Include all reaction rules, rate constants with units ($M^{-1}s^{-1}$, s^{-1}), and initial species concentrations.
2. Publish all Python scripts used for stochastic simulation and data analysis. Include exact software versions: BioNetGen version, Python version, all library dependencies (requirements.txt).
3. Perform sensitivity analysis: vary all key parameters by ±20% and report effect on primary endpoints (NANOG induction probability, Horvath clock change magnitude). This establishes the robustness of the simulation predictions.
4. Perform convergence testing: confirm that outputs are consistent across ≥1,000 independent stochastic runs. Report mean ± SD for all predicted values.
5. Release all 21,000 simulation output files as a compressed archive with a data dictionary.

Phase 2: Gate Logic Verification (Months 2-5)

Experiment 2A: Let-7 Activation Gate Functional Test

- Construct a reporter plasmid: L7Ae (with Kt in 5' UTR) driving EGFP + let-7 target sites in L7Ae 3' UTR (as per L7Ae/Kt circuit)
- Transfect in parallel: (a) adult human dermal fibroblasts (HDFs, let-7 HIGH), (b) human iPSCs (let-7 LOW), (c) H9 embryonic stem cells (let-7 LOW), (d) HEK293T (let-7 intermediate)
- Measure EGFP by flow cytometry at 24h and 48h
- Target result: ≥10-fold higher EGFP in HDFs vs. iPSCs. <2-fold is failure.
- Include controls: no-gate saRNA (constitutive), scrambled let-7 target sites

Experiment 2B: miR-294 Kill-Switch Kinetics

- Construct reporter: LEAD-7294 gate (4x, 8-mer+clamp) fused to destabilized GFP mRNA
- Transfect HDFs. At 24h post-transfection, add miR-294 mimic at 0, 500, 1000, 5000, 10,000 copies/cell (achieved by titrated synthetic mimic transfection)
- Measure GFP half-life by flow cytometry at 0, 15, 30, 60, 120, 240 min post-mimic addition
- Parallel control: same construct with 6-mer seed only (no supplemental clamp)
- Target: t½ <12 min for LEAD-7294 at 5,000 copies/cell miR-294. t½ >2h for 6-mer control. If LEAD-7294 t½ >1h, kill-switch claim is not confirmed.
- Thermodynamic validation: EMSA and ITC of LEAD-7294 sequence against AGO2-loaded RISC complex. Measure Kd directly.

Phase 3: Stoichiometry Calibration and Epigenetic Effects (Months 3-7)

Experiment 3A: OSK Ratio Calibration

- Synthesize three polycistronic mRNA constructs: 3:2:1, 1:1:1, and 2:1:3 OCT4:SOX2:KLF4 with epitope tags (HA-OCT4, Myc-SOX2, FLAG-KLF4)
- Transfect aged HDFs (passage >25 or chronologically aged, >65 year donor preferred)
- Measure protein levels by quantitative Western blot and flow cytometry at 24h, 48h, 72h to confirm actual protein ratios match design
- Readouts at 7 days: qPCR for NANOG, LIN28A, OCT4 endogenous, COL1A1, VIM, p16INK4a, SA-β-gal staining

- Readouts at 30 days: Illumina EPIC v2 methylation array for Horvath clock calculation
- Verdict: 3:2:1 is validated if it achieves NANOG <0.01% AND Horvath clock reduction ≥20% better than 1:1:1 at same dose

Experiment 3B: Full LEAD-7294 Gate + OSK saRNA in HDFs

- Synthesize complete Genesis saRNA: m1Ψ-modified, 3:2:1 OSK polycistronic cassette + LEAD-7294 3' UTR + L7Ae suppressor co-mRNA
- Formulate into SORT LNP at 5 mol% DOTAP per specifications above
- Dose aged HDFs at 0.05, 0.1, 0.5 µg/mL saRNA equivalent. Halt if IL-6 >2x baseline at any dose.
- Primary endpoints: NANOG at 24h, 48h, 72h, 7 days by qPCR and immunofluorescence; COL1A1, VIM by qPCR at 7 days; Horvath clock by EPIC array at 30, 60, 90 days
- Secondary endpoints: single-cell RNA-seq at Day 7 (minimum 5,000 cells per condition), WGBS at 30 days for off-target methylation analysis, mitochondrial OCR by Seahorse XF at 7 days
- Controls: (a) empty LNP, (b) GFP saRNA in same LNP, (c) published Tet-on OSK lentiviral system as positive control for reprogramming
- Pass criteria: NANOG <0.01%, COL1A1 retention ≥95%, Horvath clock ≥20% reduction at 90 days

Phase 4: SORT LNP Biodistribution Study (Months 5-8)

- Prepare Cy5-labeled surrogate mRNA (GFP) in SORT LNP at 0%, 5%, 15%, 50% DOTAP
- Inject C57BL/6 mice (8-12 weeks, n=5/group) via tail vein at 0.5 mg/kg RNA dose
- Euthanize at 4h, 24h, 72h. Harvest liver, lung, spleen, kidney, heart, brain.
- Quantify tissue fluorescence by IVIS imaging and qPCR for Cy5-labeled RNA
- Falsification: at 5% DOTAP, liver-to-lung ratio >1:5 constitutes failure to achieve systemic distribution
- Confirm LNP zeta potential +12-16 mV, PDI <0.10 in all formulations before injection
- Run complete blood count (CBC), liver enzymes (AST, ALT), creatinine, platelet count at 24h and 72h post-injection

Phase 5: In Vivo Aged Mouse Rejuvenation Pilot (Months 7-14)

- Model: C57BL/6 wild-type mice, ≥72 weeks of age (n=10 treatment, n=10 vehicle control)
- NRF2 pre-treatment: sulforaphane 0.5 mg/kg oral, 72h pre-injection
- Genesis treatment: SORT LNP-saRNA at 0.1 mg/kg IV, single administration
- NAD+ co-administration: NMN 500 mg/kg oral concurrent with saRNA injection
- Monitoring: Body weight, food/water intake weekly; blood draw at 2, 4, 8, 12 weeks (CBC, liver enzymes, cytokine panel IL-6, TNF-α)
- Primary efficacy endpoints: Horvath multi-tissue clock by RRBS methylation sequencing on tail biopsy samples at 4 and 12 weeks
- Secondary endpoints: Skin thickness, grip strength, treadmill endurance, cognitive Morris Water Maze at 12 weeks; organ weight and histopathology at study end
- Safety endpoints: NANOG immunohistochemistry on liver, lung, spleen, skin; karyotype of peripheral blood lymphocytes; tumor incidence monitoring for 12 months

- Falsification: any NANOG-positive cell detected; any neoplasm; Horvath clock improvement <5% at 12 weeks; IL-6 >2x baseline at any timepoint

8. COMPREHENSIVE FALSIFICATION CRITERIA

All Genesis Framework hypotheses are presented with precise, pre-specified falsification criteria. Any result meeting a falsification criterion requires public reporting and revision or retraction of the affected claim.

Hypothesis	Positive Result	Falsification Criterion	Action if Falsified
3:2:1 ratio prevents pluripotency	NANOG <0.01% at all timepoints	NANOG >0.01% by qPCR or scRNA-seq	Adjust ratio toward lower OCT4 or add KLF4 inhibitor. Re-simulate with corrected parameters.
3:2:1 outperforms 1:1:1 for rejuvenation	Horvath clock reduction ≥20% better than 1:1:1	No significant difference between ratios at 30 days	Reconsider stoichiometric hypothesis. Fall back to stringent dose control at 1:1:1.
72h saRNA pulse produces durable clock reversal	Horvath reduction ≥20% sustained at 90 days	Clock rebound to baseline before 6 months	Evaluate booster dosing interval. Consider circRNA for extended expression.
L7Ae/Kt circuit activates OSK in let-7-high cells only	≥10-fold higher OSK translation in HDFs vs. iPSCs	ON/OFF ratio <5-fold; OSK translation in iPSCs >20% of HDF levels	Re-engineer Kt binding strength or L7Ae affinity. Add additional let-7 target sites.
LEAD-7294 kill-switch degrades payload in <12 min	t½ <12 min at miR-294 >5,000 copies/cell	t½ >1h; comparable to 6-mer control	Increase number of repeats to 6. Optimize spacer length. Verify AGO2 slicing activity.
8-mer + 3' clamp superior to 6-mer alone	2-fold or greater difference in t½ vs. 6-mer control	No significant kinetic difference between 8-mer+clamp and 6-mer	Reconsider ultra-affinity architecture claim. Retain 8-mer as standard; remove clamp claim.
SORT LNP 5% DOTAP: extra-hepatic delivery	Measurable RNA expression in spleen and/or lung	Liver-to-lung ratio >1:5; near-complete hepatic sequestration	Increase DOTAP to 10-15% or switch SORT molecule. Adjust biodistribution model.
COL1A1 somatic identity retained	COL1A1 ≥95% of untreated control at Day 7	COL1A1 drop >5% or morphological transformation	Reduce saRNA dose by 50%. Shorten pulse to 48h. Increase KLF4 relative ratio.
NRF2 pre-stabilization improves outcomes	226510% greater clock reversal vs. no-NRF2 controls	<5% difference from untreated control	Remove NRF2 from protocol. Test alternative oxidative pre-conditioning agents.
Paracrine GDF11/TIMP2 network coordination	Conditioned media produces ≥10% SA-β-gal reduction in naive cells	No measurable paracrine effect in co-culture at 30 days	Re-examine SASP reversal data. Quantify GDF11/TIMP2 secretion directly.
Phase I human GrimAge reversal (future)	GrimAge reversal ≥5 years in ≥90% of n=12	GrimAge reversal <5 years in majority of	Full retraction of human efficacy claims. Return to animal model

	subjects	subjects	optimization.

9. RISK ASSESSMENT AND FAILURE MODE ANALYSIS

Risk	Severity	Likelihood	Mitigation	Detection Method
Let-7 gate failure (OSK expressed in cancer/stem cells)	CRITICAL	Moderate (novel circuit)	Rely on miR-294 kill-switch as primary safety; add miR-21 as backup; dose control	Reporter assay in iPSCs and HeLa cells before OSK construct
miR-294 kill-switch failure (too slow)	CRITICAL	Low-Moderate (biochemistry validated in principle)	6 repeats instead of 4; verify Kd empirically; add AGO2 enhancer aptamer	In vitro kill-switch kinetics assay (Phase 2B)
Uncontrolled reprogramming / teratoma	CRITICAL	Low (no c-MYC, brief pulse, dual gates)	Strict no-c-MYC design; 3:2:1 ratio; 72h pulse; dual gates; dose limits	NANOG IHC; long-term tumor surveillance >6 months
saRNA innate immune activation / cytokine storm	High	Moderate	m1Ψ modification; NRF2 pre-treatment; corticosteroid prophylaxis if IL-6 elevation detected	Cytokine panels (IL-6, TNF-α, IFN-β) at 4h, 24h, 72h post-dose
LNP toxicity (DOTAP cationic lipid)	Moderate	Moderate (known lipid effect)	5% DOTAP (not >50%); assess complement activation; ionizable lipid dominant	Platelet count, coagulation panel, complement C3/C4
Durability failure (clock rebounds quickly)	Moderate	Moderate	DNMT3A/B activity monitoring; consider booster dosing; NAD+ co-treatment	Horvath clock at 30, 60, 90, 180 days
Off-target hypermethylation	Moderate	Low-Moderate	WGBS to map all CpG changes; specific monitoring of p16INK4a, CDKN2A promoters	Whole-genome bisulfite sequencing at 30 and 90 days
saRNA mutation/escape variants	Low-Moderate	Low (RNA, not DNA)	4x kill-switch repeats for redundancy; cells are not propagated	Deep sequencing of saRNA from treated cells
Ratio stoichiometry not achieved in target cells	Moderate	Moderate	Empirical calibration by tagged-protein quantification; adjust IRES spacers; optimize T2A selection	Western blot and flow cytometry with epitope tags at 24h, 48h, 72h

10. ANTICIPATED SCIENTIFIC QUESTIONS AND RESPONSES

Q1: How does Genesis differ from existing AAV-OSK approaches?

AAV provides stable, long-duration expression but carries integration risk, manufacturing complexity, pre-existing immunity barriers, and limited dose adjustability. Genesis uses saRNA + SORT LNP: (1) non-integrating by design; (2) intrinsically transient without requiring complex dosing schedules; (3) manufactures at pharmaceutical scale using established lipid nanoparticle platforms identical to approved COVID-19 vaccines; (4) dose can be precisely adjusted; (5) carries its own cell-context safety logic (LEAD-7294 gate) not present in any published AAV-OSK approach. The 72-hour pulse is a categorically different kinetic paradigm from cyclic AAV induction. These distinctions are genuine advances, not incremental improvements.

Q2: Why is the Let-7 gate necessary if the miR-294 kill-switch already provides safety?

Defense-in-depth. The miR-294 kill-switch is a reactive safety mechanism — it terminates OSK expression after a cell has already begun to dedifferentiate. The Let-7 gate is a proactive mechanism — it prevents OSK from being expressed at all in non-somatic cells. A cancer cell that lacks let-7 AND lacks miR-294 (in early oncogenesis) would escape the kill-switch alone; the let-7 gate prevents initial expression. Together, the two gates address different threat scenarios: the let-7 gate prevents accidental expression in the wrong cell type; the miR-294 kill-switch prevents runaway dedifferentiation in the right cell type. Both are needed for the highest safety profile.

Q3: Is the 3:2:1 ratio truly safe given that OCT4 is the most powerful reprogramming factor?

This is the core experimental question. The hypothesis is that OCT4 at high relative abundance preferentially occupies aging-associated chromatin sites, not NANOG promoter sites, because the latter requires cooperative binding with SOX2 at near-equal concentrations. Published structural data supports differential OCT4 occupancy depending on collaborative factor concentrations. However, this has not been tested at exactly 3:2:1. The falsification experiment is straightforward and must be conducted before any in vivo application: head-to-head comparison of 3:2:1 vs. 1:1:1 in aged HDFs with rigorous NANOG monitoring. If the ratio fails, 1:1:1 with tighter dose control remains a viable backup.

Q4: What is the expected duration of therapeutic effect?

Simulation predictions of 6-10 months durability are based on the hypothesis that DNMT3A/B activity 're-establishes' reset methylation states at youthful set-points once OSK expression has ceased. This mechanism is proposed by analogy to published data on epigenetic memory in partial reprogramming models. In practice, durability will be highly variable between cell types and individuals, and booster dosing every 6-12 months may be required. The falsification criterion (clock rebound before 6 months) will directly resolve this question.

Q5: How was the 21,000 dual-simulation methodology conducted?

Each of the 21,000 simulation cycles ran two concurrent outputs: (1) efficacy simulation — modeling Horvath clock methylation changes at the CpG level under OSK expression with stochastic noise from Human Cell Atlas expression variability data; (2) safety simulation — simultaneously modeling NANOG induction probability, miR-294 emergence kinetics, and kill-switch response time under the same parameter set. A simulation cycle 'passed' only if both efficacy (>20% clock reduction) AND safety (NANOG <0.01%, kill-switch t½ <12 min) criteria were simultaneously met. This dual-pass requirement, across 21,000 parameter space samples, is why the Genesis Framework presents confident predictions: the design space was explored extensively before these values were proposed. Full simulation output will be publicly released under CC0 with code.

11. RESOURCE REQUIREMENTS AND VALIDATION TIMELINE

11.1 Personnel

Role	FTE / Duration	Responsibilities
Senior Molecular Biologist	1.0 FTE / 12 mo	saRNA synthesis, gate construct design, HDF experiments, cloning, sequencing
RNA Biochemist / LNP Specialist	1.0 FTE / 8 mo	LNP formulation, characterization, stability testing, saRNA modification
Epigenetics / Bioinformatics Specialist	0.5 FTE / 12 mo	Methylation array analysis, Horvath clock computation, scRNA-seq analysis, WGBS pipeline
Flow Cytometry / Imaging Technician	0.5 FTE / 8 mo	Gate reporter assays, NANOG quantification, SA-β-gal staining, IVIS biodistribution imaging
Animal Research Technician	0.5 FTE / 8 mo	Mouse husbandry, IV injections, tissue harvest, aged cohort management
Computational Modeler	0.25 FTE / 4 mo	Simulation code verification, parameter sensitivity analysis, code repository maintenance
Principal Investigator / Project Lead	0.1 FTE / 14 mo	Scientific oversight, collaboration coordination, manuscript preparation

11.2 Proposed Validation Timeline

Phase	Timeline	Key Activities	Go/No-Go Decision
1	Months 1–2	Publish simulation code; sensitivity analysis; convergence testing	Code reproducibility confirmed; simulation predictions stable
2A	Months 2–4	Let-7/L7Ae gate reporter assays; HDF vs iPSC ON/OFF ratio	ON/OFF ratio ≥10-fold. Fail: redesign L7Ae circuit.
2B	Months 3–5	miR-294 kill-switch kinetics; EMSA; ITC binding assay	t½ <1h for LEAD-7294 vs. 6-mer. Fail: increase repeats or redesign.
3A	Months 3–6	OSK ratio calibration in aged HDFs; protein ratio confirmation	3:2:1 achieves NANOG <0.01%. Fail: adjust ratio.
3B	Months 5–9	Full Genesis saRNA in SORT LNP; complete HDF in vitro package	Horvath ≥20% reversal, NANOG <0.01%, COL1A1 ≥95%. Fail: dose adjustment.
4	Months 5–8	SORT LNP biodistribution in mice; physical characterization	Extra-hepatic delivery confirmed. Fail: adjust DOTAP mol%.
5	Months 7–14	Aged mouse rejuvenation pilot; safety, efficacy, durability	Horvath ≥5% reversal, zero teratomas, IL-6 within range. Fail: full safety review.
Reporting	Months 13–16	Data integration, manuscript	Publication in Frontiers in Aging,

		preparation, bioRxiv preprint, journal submission	Aging-US, or equivalent peer-reviewed journal

12. REPRODUCIBILITY CHECKLIST FOR INDEPENDENT LABORATORIES

Any laboratory replicating this work must confirm and document the following before reporting results:

Biological Materials

- Human dermal fibroblasts: specify donor age, sex, passage number, commercial source or IRB-approved collection protocol
- iPSC or ES cell control lines: specify cell line name, passage, source. Must be confirmed pluripotent by alkaline phosphatase staining and OCT4/NANOG immunostaining.
- miR-294 mimic: specify vendor, catalog number, lot, final transfection concentration and method
- Let-7 inhibitor (for gate deactivation controls): LNA antimiR-7 or similar; specify vendor, dose, delivery method

Molecular Constructs

- All saRNA and mRNA sequences: provide complete GenBank or FASTA files including all UTR elements, LEAD-7294 gate sequence with exact spacer nucleotides, T2A sequences, and poly-A tail length
- L7Ae mRNA: provide complete sequence including Kt structural motif coordinates in the OSK 5' UTR
- Reporter constructs: provide complete sequence of all reporter plasmids used in gate functional tests

LNP Formulation

- Lipid vendors and catalog numbers for all five components
- Microfluidic mixing device specifications (manufacturer, flow rates, lipid:aqueous volume ratio)
- saRNA:lipid N:P ratio used
- QC data for each batch: DLS size, PDI, zeta potential, encapsulation efficiency, endotoxin level, saRNA integrity by Bioanalyzer

Cell Culture Conditions

- Medium, serum lot, passage at treatment, seeding density, CO2/O2 levels, temperature
- Transfection reagent and protocol (if not using LNP for in vitro studies)

Analytical Methods

- Horvath clock: specify which clock version (Horvath 2013, Hannum 2013, GrimAge, PhenoAge), methylation platform (EPIC v1 or v2, 450K, RRBS, WGBS), analysis pipeline and version
- NANOG quantification: provide primer sequences for qPCR; antibody clone and dilution for immunofluorescence; gating strategy for flow cytometry
- miR-294 quantification: specify TaqMan assay ID or primer sequences for small RNA-seq

Statistical Analysis

- Pre-specify all statistical tests before data collection

- Minimum n=3 biological replicates for all in vitro experiments
- Power analysis for animal studies
- Report all results including non-significant findings

13. BOUNDARY CONDITIONS, LIMITATIONS, AND HONEST CAVEATS

The Genesis Framework is explicitly bounded. Independent laboratories must understand what the framework claims, what it does not claim, and what must be corrected from the original FTC preprint:

What the Framework Addresses

- Epigenetic regulatory drift in mature, differentiated somatic cells with intact genomes
- Restoration of youthful CpG methylation patterns as measured by validated epigenetic clocks
- Prevention of OSK-induced pluripotency in the context of brief, low-dose, controlled delivery

What the Framework Does NOT Address

- Severe structural tissue damage, advanced organ fibrosis, or large-scale anatomical repair
- Cells with significant chromosomal instability or aneuploidy
- Catastrophic mitochondrial DNA loss or irreversible nuclear DNA damage
- Active cancer: the let-7 gate is designed to be INERT in cancer cells, making Genesis a non-cancer therapy by design

Corrections to Earlier FTC Documents

- '100% somatic identity retention': This figure must be replaced with actual measured values with error bars, n values, and statistical tests when wet-lab data are generated. 100% is not a scientifically credible value.
- 'AGO2 dwell time increased by 400%': Corrected. Published literature supports approximately 5-fold (~400% increase means 5x), but this applies to t1A affinity enhancement, not overall dwell time for the full LEAD-7294 construct. The combined construct kinetics remain to be measured.
- Climate resilience and global equity claims: These are outside the scope of a molecular biology therapeutic framework and should not appear in the scientific preprint.
- 'Vaccine' terminology: The correct terminology is 'cellular therapeutic', 'epigenetic therapeutic', or 'gene regulatory therapeutic'. The word 'vaccine' carries specific immunological definitions that do not apply to this platform.
- '21,000 cycles validate the model': Computational simulations validate internal consistency of the model; they do not validate biological truth. The correct framing is that simulations generate predictions that require biological validation.

These corrections are necessary for the document to be accepted at any peer-reviewed journal. They do not diminish the scientific value of the framework; they strengthen it by ensuring that every remaining claim is defensible.

14. GLOBAL OPEN-SOURCE RELEASE (GOSR-2026)

In accordance with the GOSR-2026 initiative, FTC Environmental Scientific Research Laboratories commits to releasing the following materials under Creative Commons CC0 (no rights reserved) immediately upon completion of internal documentation:

Release Item	Description and Access
Simulation Code	Complete BioNetGen (.bngl) and Python (.py) simulation code with parameter files, README, and example run scripts. GitHub repository.
All Sequence Files	Complete saRNA construct sequences (FASTA/GenBank): OSK cassette, LEAD-7294 gate, L7Ae suppressor mRNA, all reporter constructs.
LNP Protocol	Step-by-step LNP formulation and QC protocol. Includes microfluidic mixing parameters, lyophilization cycle, and QC thresholds.
Simulation Output Data	Compressed archive of all 21,000 simulation cycle outputs with data dictionary. Available for independent meta-analysis.
Analysis Scripts	R and Python scripts for Horvath clock calculation, NANOG quantification analysis, kill-switch kinetics fitting.
This Document	Full preprint released under CC0. No permission required for reproduction, translation, adaptation, or use in derivative works.

FTC commits to publishing all negative results, partial failures, and protocol revisions on the public GitHub repository in real time as the validation program proceeds. Scientific credibility requires full transparency, including results that do not support the framework hypotheses.

15. CONCLUSION

The Genesis Framework represents a theoretically integrated, computationally grounded, and fully falsifiable architecture for safe partial cellular rejuvenation. It is built on the convergence of four well-established biological systems — OSK reprogramming, saRNA technology, miRNA logic gating, and SORT LNP delivery — whose individual scientific foundations are solid and whose combination is unprecedented.

The core innovations of Genesis are three: first, the 3:2:1 stoichiometric hypothesis, which proposes a specific, never-before-tested ratio that may achieve rejuvenation without pluripotency; second, the LEAD-7294 dual-gate architecture, which is the first proposed application of Let-7/miR-294 logic to reprogramming safety; and third, the integrated saRNA + SORT LNP delivery platform, which offers a non-integrating, scalable, and dose-controllable alternative to AAV for systemic epigenetic therapeutics.

The 21,000 dual-simulation cycles represent a significant in silico validation effort, designed to build confidence in the parameter space before engaging in expensive and time-consuming wet-lab experiments. They do not replace wet-lab validation, but they meaningfully constrain the experimental search space and provide precise predictions to falsify.

The path forward is clear. Phase 2 gate verification and Phase 3 stoichiometry calibration are the critical bottleneck experiments. A qualified molecular biology laboratory can begin Phase 2 within weeks of receiving this

document, using commercially available reagents and standard cell culture equipment. The anticipated cost of completing through Phase 3 is estimated at $50,000-$150,000 in reagents and personnel, well within the budget of a single NIH R21 or equivalent grant.

We invite independent laboratories worldwide to replicate, challenge, and build upon this work. The Genesis Framework belongs to humanity. If it succeeds, it will represent one of the first completely open-source blueprints for a human longevity therapeutic. If it fails at specific points, those failures will teach us precisely where the boundaries of epigenetic rejuvenation lie — which is also a profound scientific contribution. Either outcome advances the field. We now hand this to the scientific community.

Genesis Core Constants (GOSR-2026 Summary): Universal OSK Ratio: OCT4:SOX2:KLF4 = 3:2:1 | Safety Gate: LEAD-7294 (Let-7/L7Ae/Kt + miR-294, 4x repeats) | Delivery: m1Ψ-saRNA in SORT LNP (5 mol% DOTAP, +12−16 mV) | Pre-conditioning: NRF2 activation 72h pre-dose | Co-treatment: NMN/NR NAD+ precursor concurrent | Zero-NANOG Standard: <0.01% cells at any timepoint

REFERENCES

1. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194-1217.

2. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-676.

3. Ocampo A, Reddy P, Martinez-Redondo P, et al. In vivo amelioration of age-associated hallmarks by partial reprogramming. Cell. 2016;167(7):1719-1733.e12.

4. Lu Y, Brommer B, Tian X, et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature. 2020;588(7836):124-129.

5. Macip CC, Hasan R, Hoznek V, et al. Gene therapy-mediated partial reprogramming extends lifespan and reverses age-related changes in aged mice. Cell Reprogram. 2024;26(1):24-32.

6. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nat Rev Genet. 2018;19(6):371-384.

7. Kusters CDJ, Horvath S. Quantification of epigenetic aging in public health. Annu Rev Public Health. 2025;46:91-110.

8. Simpson DJ, Olova NN, Chandra T. Cellular reprogramming and epigenetic rejuvenation. Clin Epigenetics. 2021;13(1):170.

9. Papapetrou EP, Tomishima MJ, Chambers SM, et al. Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation. Proc Natl Acad Sci USA. 2009;106(31):12759-12764.

10. Carey BW, Markoulaki S, Hanna JH, et al. Reprogramming factor stoichiometry influences the epigenetic state and biological properties of induced pluripotent stem cells. Cell Stem Cell. 2011;9(6):588-598.

11. Boyerinas B, Park SM, Hau A, Murmann AE, Peter ME. The role of let-7 in cell differentiation and cancer. Endocr Relat Cancer. 2010;17(1):F19-36.

12. Roush S, Slack FJ. The let-7 family of microRNAs. Trends Cell Biol. 2008;18(10):505-516.

13. Gruber AJ, Grandy WA, Balwierz PJ, et al. Embryonic stem cell-specific microRNAs contribute to pluripotency by inhibiting regulators of multiple differentiation pathways. Nucleic Acids Res. 2014;42(14):9313-9326.

14. Nakanishi H, Saito H, Itaka K. Versatile design of intracellular logic-sensing mRNA circuits for mammalian cells. ACS Synth Biol. 2020;9(1):21-30.

15. Wroblewska L, Kitada T, Endo K, et al. Mammalian synthetic circuits with RNA binding proteins for RNA-only delivery. Nat Biotechnol. 2015;33(8):839-841.

16. Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol. 2020;15(4):313-320.

17. Wei T, Cheng Q, Min YL, Olson EN, Siegwart DJ. Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing. Nat Commun. 2020;11(1):3232.

18. Pardi N, Tuyishime S, Muramatsu H, et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release. 2015;217:345-351.

19. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-297.

20. Yang JH, Petty CA, Dixon-McDougall T, et al. Chemically induced reprogramming to reverse cellular aging. Aging. 2023;15(13):5966-5989.

21. Huysmans H, Zhong Z, De Temmerman J, et al. Expression kinetics and innate immune response after electroporation and LNP-mediated delivery of a self-amplifying mRNA in the skin of mice. Mol Ther Nucleic Acids. 2019;17:867-878.

22. Becker WR, Ober-Blobaum JL, Bhatt M, et al. High-throughput analysis reveals rules for target RNA binding and cleavage by AGO2. Mol Cell. 2019;75(4):741-755.e11.

Declaration of Interests, Author Contributions, and Ethics

Conflicts of Interest: The authors declare no financial or other conflicts of interest. No external funding was received for this work. FTC Environmental Scientific Research Laboratories is an independent nonprofit scientific research laboratory operating within Forward Thinking Communities, Reading, Pennsylvania.

Author Contributions: FTC Scientific Group: conceptualization, computational modeling, framework development, document preparation. Cesar Cepeda: executive direction, project oversight, institutional governance.

Ethics Statement: This document contains theoretical framework and proposed experimental protocols. No human subjects research or animal experiments are described as having been conducted by FTC. All proposed in vivo experiments described in Section 7 Phase 5 must be conducted under appropriate Institutional Animal Care and Use Committee (IACUC) approval by the implementing laboratory. Any future human studies must follow applicable regulatory pathways including IND filing with the FDA or equivalent national agency.

© 2026 FTC Environmental Scientific Research Laboratories, Forward Thinking Communities. Released under Creative Commons CC0. No rights reserved. Free to reproduce, adapt, distribute, and build upon for scientific purposes.

Correspondence: Cesar Cepeda | cepedainvestments@gmail.com | 484-721-1969 | 50 N. 4th Street, Office 1, Reading, Pennsylvania 19601, USA

GOSR-2026 • Open Science • Forward Thinking Communities • "Let's Change Humanity"